Protective effect of Monflu on lipopolysaccharide-induced acute lung injury in Wistar rats

Monflu is a granule that develops from Lider-7 traditional prescription, and used for the treatment of respiratory contagious diseases.This study aimed to evaluate quality control, total biological activity and to analyze the activity of this substance in Wistar rat with acute lung injury (ALI).Seventy Wistar rats were randomized into four groups as follows: control group, Lipopolysaccharide (LPS) group, and LPS+Monflu groups (242 mg/kg and 484 mg/kg Monflu before LPS injection).Results showed that, Monflu contained 6g granule in a packet, alkaloids were 95±16.6 µg/g, phenols were 3.36±0.45mg/g, flavonoids were 1.18±0.1 mg/g.The rats pretreated with Monflu high and low doses had significantly decreased levels of interleukin (IL)-1β (p=0.001 at 3-12 h), IL-6 (p=0.001 at 9 and 12 h) and tumor necrosis factor (TNF)-α (p=0.05 at 9 and 12 h).The rats pretreated with Monflu groups significantly increased levels of prostaglandin E2 (PGE2) at 3, 6, and 9 h (p<0.05),but it had reduced at 12 hours (p=0.001).Monflu groups showed significantly decreased inflammation and change of pulmonary structure.This study showed that Monflu exhibited a protective effect against LPS-induced ALI which was revealed to be mediated by suppressing the release of pro-inflammatory cytokines.